- references:
  - doi: 10.1126/science.abd0827
    firstAuthor:
      surname: Hansen
      givenNames: Johanna
    year: 2020
    journal: Science
  - doi: 10.1126/science.abd0831
    firstAuthor:
      surname: Baum
      givenNames: Alina
    year: 2020
    journal: Science
  - doi: 10.1101/2020.08.02.233320
    firstAuthor:
      surname: Baum
      givenNames: Alina
    year: 2020
    journal: bioRxiv
  antibodies:
  - name: REGN10933 + REGN10987
  description: |-
    REGN10933 + REGN10987 is a combination of two monoclonal antibodies targeting the SARS-CoV-2 spike protein, which have begun clinical trials in June 2020.
  company: Regeneron
  phase: III
  clinicalTrials: |-
    NCT04425629 (Outpatient; Phase I, II, III; n=2100)
    NCT04426695 (Hospitalized; Phase I, II, III; n=2970)
    NCT04452318 (Prevention; Phase III)
    NCT04519437
- references:
  - doi: 10.1101/2020.09.30.318972
    firstAuthor:
      surname: Jones
      givenNames: Bryan E.
    year: 2020
    journal: bioRxiv
  - doi: 10.1038/s41586-020-2381-y
    firstAuthor:
      surname: Shi
      givenNames: Rui
    year: 2020
    journal: Nature
  antibodies:
  - name: LY-CoV555 (LY3819253)
  - name: LY-CoV555 + LY-CoV016(LY3832479)
  description: |-
    LY3819253 (LY-CoV555) is a monoclonal antibody targeting the SARS-CoV-2 spike protein, which have begun clinical trials in June 2020.
  company: Lilly / AbCellera
  phase: III
  clinicalTrials: |-
    NCT04411628 (Phase I; n=40)
    NCT04427501 (BLAZE-1; Phase II; n=800)
    NCT04497987 (BLAZE-2; Prevention; Phase III; n=2400)
    NCT04518410 (Outpatients; Phase III; n=2000)
    NCT04501978
- references: []
  antibodies:
  - name: TY027
  description: |-
    TY027 is a monoclonal antibody targeting the SARS-CoV-2 spike protein, which began clinical trials in June 2020.
  company: Tychan Pte
  phase: I
  clinicalTrials: |-
    NCT04429529
- references:
  - doi: 10.1038/s41586-020-2381-y
    firstAuthor:
      surname: Shi
      givenNames: Rui
    year: 2020
    journal: Nature
  antibodies:
  - name: JS016
  description: |-
    JS016 is a monoclonal antibody targeting the SARS-CoV-2 spike protein, which began clinical trials in June 2020.
  company: Shanghai Junshi Bioscience
  phase: I
  clinicalTrials: |-
    NCT04441918
- references: []
  antibodies:
  - name: BRII-196
  description: |-
    BRII-196 is a SARS-CoV-2 monoclonal antibody that blocks viral entry to neutralize SARS-CoV-2 infection. It is being studied in clinical trials as a treatment for COVID-19.
  company: Brii Biosciences
  phase: I
  clinicalTrials: |-
    NCT04479631
    NCT04479644
- references: []
  antibodies:
  - name: AZD7442 (AZD8895 and AZD1061)
  description: |-
    AZD7442 is a potential combination monoclonal antibody therapy (AZD8895 + AZD1061) being developed by AstraZeneca for the prevention and treatment of COVID-19.
  company: AstraZeneca / Paraxel
  phase: I
  clinicalTrials: |-
    NCT04507256
- references: []
  antibodies:
  - name: CT-P59
  description: |-
    CT-P59 is a monclonal antibody targeting the SARS-CoV-2 spike protein, which began clinical trials in August 2020.
  company: Celltrion
  phase: I
  clinicalTrials: |-
    NCT04525079
- references: []
  antibodies:
  - name: MW33
  company: Mabwell Bioscience
  phase: I
  clinicalTrials: |-
    NCT04533048
- references: []
  antibodies:
  - name: BGB DXP593
  company: BeiGene
  phase: I
  clinicalTrials: |-
    NCT04532294
- references: []
  antibodies:
  - name: STI-1499
  description: |-
    STI-1499 is a monoclonal antibody targeting the SARS-CoV-2 spike protein, which has begun clinical trials.
  company: Sorrento Therapeutics
  phase: I
  clinicalTrials: |-
    NCT04454398
- references: []
  antibodies:
  - name: SCTA01
  description: |-
    SCTA01 is an anti-SARS-CoV-2 monoclonal antibody being studied in clinical trials to neutralizes the SARS-CoV-2 virus and prevent viral entry.
  company: Sinocelltech
  phase: I
  clinicalTrials: |-
    NCT04483375
- references:
  - doi: 10.1038/s41586-020-2349-y
    firstAuthor:
      surname: Pinto
      givenNames: Dora
    year: 2020
    journal: Nature
  antibodies:
  - name: VIR-7831
  company: Vir Biotechnology, GSK
  phase: III
  clinicalTrials: |-
    NCT04545060
- references: []
  antibodies:
  - name: COVI-AMG (STI-2020)
  company: Sorrento Therapeutics
  phase: I
  clinicalTrials: |-
    NCT04584697
- references: []
  antibodies:
  - name: HLX70
  company: Hengenix Biotech Inc
  phase: I
  clinicalTrials: |-
    NCT04561076
- references: []
  antibodies:
  - name: ADM03820
  company: Ology Bioservices
  phase: I
  clinicalTrials: |-
    NCT04592549
- references: []
  antibodies:
  - name: HFB30132A
  company: HiFiBiO Therapeutics
  phase: I
  clinicalTrials: |-
    NCT04590430
